Ascentage Pharma
Updated: January 15, 2026
Dajun Yang, co-founder, chairman and CEO
Country: China | Funding: $504.7M (+)
Founded: 2009
Website: https://www.ascentage.com/
Ascentage Pharma is a China-based, global-oriented company focused on the discovery and development of targeted small molecule anti-cancer therapies. The company leverages own breakthrough chemistry to synthesize inhibitors that target proteins (Bcl-2, Bcl-2/Bcl-xL, IAP, and MDM2) and signaling pathways that define key cancer hallmarks (e.g., BCR-ABL1, ALK, and FAK inhibitors). It also develops therapies such as PROTACs (Protein Acid Carcinogenesis Acids) that target traditionally untreatable proteins involved in oncogenesis. The company is conducting clinical trials of drugs against chronic lymphocytic leukemia, acute myeloid leukemia, small lymphocytic lymphoma, adrenocortical carcinoma, malignant peripheral nerve sheath tumor, and non-small cell lung cancer.
Founded: 2009
Website: https://www.ascentage.com/
Ascentage Pharma is a China-based, global-oriented company focused on the discovery and development of targeted small molecule anti-cancer therapies. The company leverages own breakthrough chemistry to synthesize inhibitors that target proteins (Bcl-2, Bcl-2/Bcl-xL, IAP, and MDM2) and signaling pathways that define key cancer hallmarks (e.g., BCR-ABL1, ALK, and FAK inhibitors). It also develops therapies such as PROTACs (Protein Acid Carcinogenesis Acids) that target traditionally untreatable proteins involved in oncogenesis. The company is conducting clinical trials of drugs against chronic lymphocytic leukemia, acute myeloid leukemia, small lymphocytic lymphoma, adrenocortical carcinoma, malignant peripheral nerve sheath tumor, and non-small cell lung cancer.
